- Home
- GUTS
GUTS
FRACTYL HEALTH INC
as 06-18-2025 4:00pm EST
Stocks
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | BURLINGTON |
| Market Cap: | 58.8M | IPO Year: | 2024 |
| Target Price: | $10.00 | AVG Volume (30 days): | 362.1K |
| Analyst Decision: | Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.84 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.87 - $5.50 | Next Earning Date: | 05-13-2025 |
| Revenue: | $60,000 | Revenue Growth: | -59.46% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest FRACTYL HEALTH INC News
GUTS Breaking Stock News: Dive into GUTS Ticker-Specific Updates for Smart Investing
MT Newswires
11 hours ago
Fractyl Health Obtains 2 US Patents for Duodenal Resurfacing
GlobeNewswire
13 hours ago
Fractyl Health Reinforces Intellectual Property Leadership in Metabolic Disease with Two New U.S. Patents Directed to Duodenal Resurfacing
TipRanks
5 days ago
Biotech Alert: Searches spiking for these stocks today
GlobeNewswire
6 days ago
Fractyl Health to Present New Preclinical Data from its Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Platform at the American Diabetes Association's 85th Scientific Sessions
GlobeNewswire
15 days ago
Fractyl Health and Bariendo Sign Letter of Intent to Prepare for Potential Offering of Revita® Across its Bariatric and Metabolic Endoscopy Centers Nationwide
MT Newswires
a month ago
Fractyl Health Submits First Module of EU Trial Application for Gene Therapy RJVA-001
GlobeNewswire
a month ago
Fractyl Health Advances Rejuva® Gene Therapy Platform with Submission of First Clinical Trial Application Module in Europe for RJVA-001 in Type 2 Diabetes
GlobeNewswire
a month ago
Fractyl Health Unveils New Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Preclinical Data Highlighting Durable Potency and Safety with Limited Systemic GLP-1 Exposure at ASGCT 2025
Compare GUTS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GUTS FRACTYL HEALTH INC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.